ProMIS Neurosciences Inc.NASDAQ: PMN

ProMIS Neurosciences to Participate in Upcoming Conferences in November

· Issued by ProMIS Neurosciences Inc. via GlobeNewswire

Summary by 6ix AI

ProMIS Neurosciences, a clinical-stage biotechnology company developing antibody treatments and vaccines aimed at toxic misfolded proteins in brain-degenerating diseases, will take part in conferences in November 2026. President and CEO Neil Warma will give presentations and fireside chats, and leadership team members will be available for one-on-one meetings.

Key details

  • Guggenheim 3rd Annual Healthcare Innovation Conference, Boston, MA (November 9-11): fireside chat on Tuesday, November 10, at 2:30 p.m. ET, with a webcast. Stifel 2026 Healthcare Conference, New York, NY (November 10-12): presentation on Wednesday, November 11, at 2:40 p.m. ET, with a webcast.
  • UBS Global Biopharma Conference, London, UK (November 16-17): presentation on Monday, November 16, at 10 a.m. GMT, with a webcast. The company will also attend the Jefferies Global Healthcare Conference in London, UK (November 16-19).
  • Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston, MA (November 16-19): poster P047, titled Interim Safety and Biomarker Analysis of PRECISE-AD, on November 16-17. The data were previously presented on July 28, 2026.
  • 9th Annual Evercore Healthcare Conference, Miami, FL (November 30-December 2): fireside chat on Wednesday, December 2, at 9:10 a.m. ET, with a webcast.

6ix AI wrote this summary from the release below and checked it against the release.

CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming November 2026 conferences. Presentations and fireside chats will be delivered by Neil Warma, President and Chief Executive Officer. Members of the Company’s leadership team will be available for one-on-one meetings at the conferences.

Conference details below:

November 9-11: Guggenheim 3rd Annual Healthcare Innovation Conference
Location: Boston, MA
Fireside chat: Tuesday, November 10, 2:30 p.m. ET, Wheeler Room
Webcast link: Click Here

November 10-12: Stifel 2026 Healthcare Conference
Location: New York, NY
Presentation: Wednesday, November 11, 2:40 p.m. ET, Spellman Room
Webcast link: Click Here

November 16-17: UBS Global Biopharma Conference
Location: London, UK
Presentation: Monday, November 16, 10 a.m. GMT
Webcast link: Click Here

November 16-19: Jefferies Global Healthcare Conference
Location: London, UK

November 16-19: Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Location: Boston, MA
Poster presentation: Monday, Nov 16-Tues Nov 17th
Poster title: Poster # P047, Interim Safety and Biomarker Analysis of PRECISE-AD*
(*data previously presented on July 28, 2026)

November 30-December 2: 9th Annual Evercore Healthcare Conference
Location: Miami, FL
Fireside chat: Wednesday, December 2, 9:10 a.m. ET, Sevilla A
Webcast link: Click Here

About ProMIS Neurosciences Inc.

ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS’ lead asset in Phase 1b development, PMN310, is a humanized IgG1 monoclonal antibody designed to selectively target only the toxic oligomers of amyloid-beta (AβOs), believed to be among the earliest and most damaging drivers of Alzheimer’s disease, while avoiding binding to amyloid plaques and vascular deposits. ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).

Investor Relations Contact:

Carie Pierce, VP, Investor Relations & External Affairs

[email protected]

View original source (GlobeNewswire)ProMIS Neurosciences Inc. on 6ix

Story so far

Earlier from ProMIS Neurosciences

Later from ProMIS Neurosciences

All ProMIS Neurosciences news releases